Key result
Ibuprofen initiation for acute pericarditis linked to ~25% lower 1-year major cardiovascular events risk.
Why the study?
Ibuprofen treats acute pericarditis, but high doses have been linked to increased cardiovascular risks, leaving its cardiovascular safety in this setting unclear.
Does ibuprofen use increase the risk of major adverse cardiovascular events in adults with first-time acute pericarditis?
Cohort (n=12,381)
Does ibuprofen use increase the risk of major adverse cardiovascular events in adults with first-time acute pericarditis?
Ibuprofen use for acute pericarditis is not associated with an increased risk of major adverse cardiovascular events, supporting its cardiovascular safety in current clinical practice.
Answers are grounded in this paper and cite their sources.
Supports ibuprofen safety in acute pericarditis without MACE increase; leaves open causal effects pending randomized confirmation.
Purpose: Ibuprofen is used to treat acute pericarditis, but high-dose ibuprofen has also been associated with increased cardiovascular risks. We examined the cardiovascular safety of using ibuprofen for acute pericarditis. Patients and Methods: A Danish nationwide, population-based cohort study including patients ≥ 18 years with first-time acute pericarditis (n=12,381) during 1996– 2020 was conducted. Ibuprofen use was modelled in two ways: First, we considered patients exposed based on the tablet strength of their first ibuprofen filling (a proxy for an intention-to-treat analysis). Second, we considered patients exposed in a time-varying manner (a proxy for an as-treated analysis). The primary outcome of major adverse cardiovascular events (MACE) was a composite of myocardial infarction, ischemic stroke, congestive heart failure, and cardiovascular death. Results: In the intention-to-treat analysis, the 1-year risk of MACE was 1.37% (95% confidence interval [CI]: 1.03– 1.79) for ibuprofen initiators and 4.32% (95% CI: 3.89– 4.78) for non-initiators. Compared with non-initiators within 1-year follow-up, the adjusted hazard ratio for MACE was 0.75 (95% CI: 0.67– 0.85) for initiators overall, 0.38 (95% CI: 0.28– 0.52) for initiators of > 400 mg tablets, and 0.87 (95% CI: 0.76– 0.99) for initiators of ≤ 400 mg tablets. In the as-treated analysis, compared with no use, the hazard ratio associated with ibuprofen use was 0.69 (95% CI: 0.54– 0.89) for MACE, 0.82 (95% CI: 0.54– 1.26) for myocardial infarction, 0.74 (95% CI: 0.45– 1.22) for ischemic stroke, 0.67 (95% CI: 0.47– 0.96) for congestive heart failure, and 0.60 (95% CI: 0.31– 1.17) for cardiovascular death. Conclusion: Ibuprofen use for acute pericarditis was not associated with increased cardiovascular risks, supporting its safety in current practice.
No takes yet. Share an insight, caveat, or question.
Eika et al. (2024) conducted a cohort in First-time acute pericarditis (n=12,381). Ibuprofen vs. Non-initiators was evaluated on Major adverse cardiovascular events (MACE) (HR 0.75, 95% CI 0.67-0.85). Ibuprofen initiation for acute pericarditis was associated with a reduced risk of major adverse cardiovascular events compared with non-initiation within 1-year follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: